Also the selective ER degrader Fulvestrant has an important role in breast cancer treatment (Nathan and Schmid, 2017) and a number of additional novel therapeutic compounds with improved pharmacokinetics act at the receptor level and are under investigation (Furman et al., 2019). This evidence concerns the gene ESR1 and breast carcinoma.